Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — Investor Presentation (November 2022)
27 slides from Nuvectis Pharma's investor presentation, November 2022
Slide 1: Nuvectis Pharma: Innovative Precision Medicine
Nuvectis Pharma Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology November 2022 (NASDAQ: NVCT)
Slide 2: Forward Looking Statements
Forward Looking Statements Nuvectis Pharma, Inc. Certain statements in this presentation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Statements other than those of his
Slide 3: Key Highlights
Key Highlights Precision Medicine Innovation for Serious Conditions of Unmet Medical Need in Oncology Management team with a proven Novel pipeline of rationally In the next 12 months track record of clinical and designed precision targeted regulatory success therapies • NXP800 - Completion of Phase
Slide 4: Leadership Team
Leadership Team Track Record of Success Ron Enrique Shay Bentsur Poradosu, PhD Shemesh CHAIRMAN & CEO CSO & CBO CDO & COO • 20+ years senior leadership • 20+ senior leadership • 15+ years of experience in drug experience experience development • CEO (Keryx and Urogen), C-Suite • Roles in Business an
Slide 5: Nuvectis Pipeline
Nuvectis Pipeline Unique Precision Medicine Drug Candidates Product Candidate IND enabling Phase 1a Phase 1b Phase 2 Phase 3 Status Ovarian Clear Cell Carcinoma Ovarian Phase 1a dose escalation ongoing NXP800 Endometrioid Carcinoma Phase 1b to begin in Q1 2023 Gastric Cancer SRC-kinase driven solid
Slide 6: About NXP800
About NXP800 A Novel HSF1 Pathway Inhibitor
Slide 7: NXP800 Key Highlights
NXP800 Key Highlights at the Institute of Cancer Research (ICR) in the UK. Discovered and optimized The ICR also discovered Zytiga, a leading drug for metastatic prostate cancer. targeting a well-characterized biologic pathway with established relevance in Unique, novel molecule oncology: Heat Shock
Slide 8: NXP800 Antitumor Activity in ARID1a-Mutated Ovarian Cancer Xenografts vs. Cisplatin
NXP800 Demonstrated Substantial Antitumor Activity in ARID1a-Mutated Ovarian Cancer Xenografts vs. Cisplatin Model 1: SKOV-3 Model 2: TOV-21G NuvectisPharma, Inc. I Corporate presentation 8
Slide 9: ARID1a-Mutated Ovarian Carcinoma
ARID1a-Mutated Ovarian Carcinoma Found Almost Exclusively in OCCC and EOC • The American Cancer Society estimates that approximately 19,880 women will receive a new diagnosis of ovarian cancer in the United States in 2022 (https://cancerstatisticscenter.cancer.org/#!/cancer-site/Ovary) Ovarian Cance
Slide 10: NXP800 Antitumor Activity in ARID1a-Mutated Gastric Carcinoma Xenograft
NXP800 Demonstrated Substantial Antitumor Activity in an ARID1a-Mutated Gastric Carcinoma Xenograft SNU-1 Day 28 Relative Tumor Tumor Growth Inhibition Volume (RTV28) a (TGI) b Vehicle 2.67 -- NXP800 (35 mg/kg) 0.74 72% a. RTV28 = [avg. tumor volume D28] / [avg. tumor volume at baseline]; value <1 i
Slide 11: ARID1a-Mutated Gastric Carcinoma
ARID1a-Mutated Gastric Carcinoma • The American Cancer Society estimates that approximately 26,380 people will receive a new diagnosis of gastric cancer in the United States in 2022 (https://cancerstatisticscenter.cancer.org/#!/cancer-site/Stomach) Gastric Cancer Net Incidence 100% ARID1a-Mutated Ga
Slide 12: Significant Potential in Additional Tumor Types
Significant Potential in Additional Tumor Types Patient Selection Strategy Estimated Estimated Number of Indication Incidence Patients with ARID1a (US) protein loss (US) ARID1a is a common genetic mutation that can potentially be used as a patient selection Ovarian Clear Cell Carcinoma 1,988 1,325 s
Slide 13: NXP800: First in class HSF1-pathway inhibitor
First in class HSF1-pathway inhibitor HSF1 ACTIVATION implicated in several solid tumors NXP800 A Novel HSF1- FOCUSED Clinical / regulatory strategy Pathway Inhibitor PHASE 1a ONGOING Phase 1b expected to begin in Q1 2023 BROAD POTENTIAL ARID1a is mutated in OCCC, ovarian endometrioid, gastric, uter
Slide 14: About NXP900
About NXP900 A Novel SRC / YES1 inhibitor
Slide 15: NXP900 Key Highlights
NXP900 Key Highlights Novel, Selective and highly potent discovered at the University of Edinburgh, Scotland. SRC/YES1 kinase inhibitor - Unique MoA providing for the complete shutdown of the SRC signaling pathway Clearly differentiated - High selectivity without immune suppression effect IND-enabli
Slide 16: SRC / YES1 Kinase Signaling
SRC / YES1 Kinase Signaling SRC-mediated Signal Transduction Involves Catalytic and Scaffolding Activities Scaffold Domain SH2 and SH3 domains of SRC kinase family members constitute a scaffold to which other pro-oncogenic signaling molecules are Complete shutdown of recruited inducing pro-oncogenic
Slide 17: NXP900 Novel and Differentiated Mechanism of Action
NXP900 Novel and Differentiated Mechanism of Action NXP900: Complete shutdown of Other multi-kinase inhibitors: No inhibitor: Fully active SRC the SRC pathway Partial shutdown of the SRC pathway NON- FNCTIONAL scaffolding site Fully functional Fully functional scaffolding site scaffolding site - Bin
Slide 18: NXP900 Selectivity
NXP900 Selectivity Kinome Profiling Reveals High Selectivity Compared With Dasatinib NXP900 Dasatinib Kinome-wide activity profile of NXP900 - enzymatic inhibition screen was performed by Carna Biosciences, against 326 wildtype and mutant kinases. Circles identify kinase targets of NXP900 (0.5μM, li
Slide 19: NXP900 Re-Sensitizes Resistant NSCLC Cells to Osimertinib
NXP900 Re-Sensitizes Resistant NSCLC Cells to Osimertinib* Published in Nature Communications by the AstraZeneca R&D Group, April 2022 A) Osimertinib dose–response curve in PC9 NSCLC parental cells compared to two lines derived to have acquired osimertinib resistance, (96h treatment). B) ECF-506 (NX
Slide 20: NXP900 in TNBC
NXP900 in TNBC Superior Preclinical Activity vs. Dasatinib NXP900 40 mg/kg, QD NXP900 inhibited tumor growth in an orthotopic model of triple negative breast cancer (TNBC) in immunocompetent animals, showing superiority vs dasatinib, and substantial long-term effect after NXP900 NXP900 treatment com
Slide 21: NXP900 in TNBC (Cont.)
NXP900 in TNBC (Cont.) Eradication of TNBC-induced Bone Metastatic Lesions A) IHC - pY418 inhibition. B) Quantitative analysis of SRC-pY418 C) Tumor volume, days 2 vs 0 D) In vivo study in FVB immunocompetent mice E) In vivo study in CD1 immunocompromised mice F) Tumor volume - end of treatment G) I
Slide 22: NXP900 in Group 4 Medulloblastoma Preclinical Model
NXP900 is Highly Effective in a Preclinical Model of Group 4 Medulloblastoma SRC Signaling is a Hallmark of Group 4 Medulloblastoma (Forget et al., Cancer Cell, 2018, 34, 379-395) • SrcCA/DNp53 tumour cells (Forget et al, 2018) were cultured in vitro and transduced using lentivirus expressing Lucife
Slide 23: YES1 Gene Amplification
YES1 Gene Amplification Patient Selection Strategy Estimated Number of Estimated Incidence Indication Patients with YES1 Gene (US) Amplification (US) YES1 gene amplification can Esophageal squamous cell carcinoma 5,778 364 potentially be used as a patient selection strategy in a variety of Esophagea
Slide 24: NXP900 Opportunity in Solid Tumors
NXP900 provides an opportunity to treat solid tumors with a SRC/YES1 inhibitor SRC (OVERACTIVATION) are implicated in several solid tumors. However, AND YES1 (GENE the existing multi-kinase SRC/YES1 inhibitors, AMPLIFICATION) including dasatinib, which are approved for NXP900 CML/ALL, have only show
Slide 25: Financial Highlights
Financial Highlights • Cash runway into H2 2024 Shares Cap Table • IPO in February 2022 at $5 per share (in millions) Common Shares Outstanding 14.6 • Current stock price is ~$7.00 per share, Fully Diluted Shares 15.2 market capitalization of ~$100M Management Ownership ~35% • Covering analysts incl
Slide 26: Key Highlights
Key Highlights Experienced Management Team Focused on Value Creation Unique pipeline of rationally-designed Over the next 12 months precision targeted therapies • NXP800 - Completion of dose • NXP800: A potent, clinical stage HSF1- pathway inhibitor escalation and initiation of phase 1b in the targe
Slide 27: Nuvectis Pharma: Innovative Precision Medicine
Nuvectis Pharma Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology November 2022 (NASDAQ: NVCT)
Nuvectis Pharma — Investor Presentation (November 2022) on 6ix